From The Editor
-
3 Things You Didn’t Hear Coming Out Of JPM
2/6/2024
You’ve heard San Francisco was buzzing with cautious optimism last month. You’ve seen the M&A activity that’s buoying spirits and you know inflation and interest rates are stabilizing, if not improving. You may not have considered these three trendlines, offered by a guy who spent his time at JPM doing more listening than anything.
-
2023 ADC Roundup: A Year Of Collaboration And Licensing Deals
1/3/2024
Despite the continuation of a poor funding climate in biotech, 2023 was a big year for antibody-drug conjugates (ADCs).
-
RNA Vaccines: Just Scratching The Surface
12/28/2023
RNA vaccines have shown promise in preventing infectious diseases and treating cancer, but clinical development varies markedly between the two. HDT Bio’s Dr. Berglund discusses this and how they can be improved.
-
How Creative Licensing Can Improve Patient Access
11/16/2023
Members of Caring Cross and UC Berkeley's Innovative Genomics Institute and Office of IP And Industry Research Alliances discuss the important role technology transfer offices (TTOs) play in improving ATMP accessibility. TTOs can accomplish this by designing "strings-attached" research and licensing deals upstream in product development.
-
Legal And IP Protection For New Biotechs
10/31/2023
Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs.
-
Targeting The Gut–Brain Axis With Live Biotherapeutic Products
9/8/2023
Treating seizures with bacteria — Bloom Science's CEO, Dr. Christopher Reyes, explains how his company aims to leverage the gut–brain axis using live biotherapeutic products (LBP).
-
ADC Advancements Allowing For Higher DAR
8/22/2023
A high drug-antibody-ratio (DAR) used to mean higher off-target toxicity for ADCs. Now, thanks to improvements in linker technology and antibody targeting, higher DARs can allow for improved efficacy.
-
How Linker Technology Is Driving ADC Development
8/4/2023
If you’re still not excited about antibody drug conjugates (ADCs), “there’s an issue with you.” That’s the passionate, bullish sentiment (jokingly) held by Dr. Joe Daccache, project leader at DeciBio. Here, Daccache explains how innovations in linker technology are advancing the field of ADCs.
-
Tech-Heavy Drug Discovery Yields Deep Pipeline
8/3/2023
Recursion Cofounder and CEO, Chris Gibson, Ph.D. is creating a map of human biology comparable to Google’s ongoing effort to map every street on the planet. He shared why that's so important, and how it's informing Recursion's rapid drug discovery efforts.
-
Engineering Antibodies In A Box?
7/27/2023
Machines aren’t smart enough to engineer optimal, disease-specific antibodies without data that’s properly generated, captured, and structured. That’s why LabGenius Founder Dr. James Field says the key to success is neither human-derived data, nor machine-enabled design. It’s the organizational engineering feat of bringing the two together.